<DOC>
	<DOCNO>NCT01885000</DOCNO>
	<brief_summary>The purpose study evaluate patient-reported outcome ( feedback patient ) new drug treatment erythema rosacea ( central facial redness ) . The feedback patient receive active drug compare feedback patient receive placebo .</brief_summary>
	<brief_title>Patient-Reported Outcome Of Facial Erythema ( PROOF )</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Male female subject age 18 year old , A clinical diagnosis facial rosacea , A Patient SelfAssessment score 4 ( severe ) Baseline prior study drug application , A Clinician 's Erythema Assessment ( CEA ) score 3 ( moderate ) 4 ( severe ) Baseline prior study drug application , More 5 facial inflammatory lesion ( papule pustule ) rosacea , Any uncontrolled chronic serious disease medical condition may either interfere interpretation clinical trial result , put subject significant risk subject participate clinical trial judge investigator , Known suspect allergy sensitivity component study drug , include active ingredient brimonidine tartrate ( see Investigator 's Brochure ) , Female pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>